(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.83%.
Edgewise Therapeutics's earnings in 2026 is -$197,222,000.On average, 15 Wall Street analysts forecast EWTX's earnings for 2026 to be $142,694,965, with the lowest EWTX earnings forecast at -$257,565,552, and the highest EWTX earnings forecast at $1,217,886,703. On average, 14 Wall Street analysts forecast EWTX's earnings for 2027 to be -$205,142,339, with the lowest EWTX earnings forecast at -$366,126,240, and the highest EWTX earnings forecast at -$53,596,138.
In 2028, EWTX is forecast to generate -$201,362,916 in earnings, with the lowest earnings forecast at -$299,074,050 and the highest earnings forecast at -$20,526,180.